IMPORTANCE Identification of patients with hereditary renal cell carcinoma (RCC) is important for cancer screening and, in patients with advanced disease, for guiding treatment. The prevalence of cancer-related germline mutations in patients with advanced RCC and the phenotypes associated with some rare mutations are unknown.
R enal cell carcinoma (RCC) is among the 10 most frequently diagnosed cancers in the United States, affecting approximately 64 000 patients per year. 1 Approximately 30% of patients are initially diagnosed with locoregional (stage III) or metastatic disease. 2, 3 Renal cell carcinoma comprises a heterogenous group of cancers. Clear cell RCC (ccRCC), the most common subtype, is characterized by loss of function of the von Hippel-Lindau (VHL) protein. 4 Additional histologic subtypes are collectively known as non-clear cell (nccRCC) and include papillary type I and II, chromophobe, microphthalmia transcription factor family translocation associated, collecting duct, medullary, and other rare subtypes.
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Tumors that do not meet criteria for any established subtypes are categorized as unclassified. 6 Several autosomal dominant inherited cancer syndromes predispose patients to ccRCC and nccRCC. 7, 8 Among these are VHL, hereditary leiomyomatosis and RCC (HLRCC), hereditary papillary RCC, and Birt-Hogg-Dubé, caused by germline mutations in VHL (OMIM 608537), FH (OMIM 136850), MET (OMIM 164860), and FLCN (OMIM 607273), respectively. 4 There is also an increased risk of RCC among patients with germline mutations in BAP1 (OMIM 603089), SDHB (OMIM 185470), SDHC (OMIM 602413), SDHD (OMIM 602690), TSC1 (OMIM 605284), TSC2 (OMIM 191092), and MITF (OMIM 156845).
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Inherited RCC syndromes are thought to account for 5% of all cases; however, these estimates were derived from mostly early-stage RCC, and no studies have specifically looked at advanced disease.
14,15 Recent studies [16] [17] [18] suggest that germline mutations may be more frequent in patients with advanced cancer compared with those with early-stage disease. Identifying patients with inherited mutations has become particularly relevant because mutations in certain genes, such as FH and MET, can guide systemic therapy or clinical trial eligibility. [19] [20] [21] [22] Furthermore, identification of germline mutations could provide useful information for patients and family members for cancer risk stratification and early detection. Despite the potential benefits of identifying germline carriers, there is still uncertainty of who should be referred for genetic testing.
We assessed the frequency of germline mutations in 76 cancer-associated genes in patients with advanced RCC unselected for inherited syndrome risk factors, such as age at onset, multifocal disease, or family history. Our aims were to examine the prevalence of germline mutations in known RCC predisposition genes and other cancer-associated genes and to identify clinical and pathologic factors associated with germline mutations.
Methods

Patient Selection
From October 1, 2015, through July 31, 2017, a total of 267 patients with advanced (AJCC stage III or IV) RCC seen in medical oncology or urology clinics at Memorial Sloan Kettering Cancer Center (MSKCC) were offered germline sequencing and disclosure of results under an institutional protocol of matched tumor-germline DNA sequencing. All patients with advanced nccRCC or advanced ccRCC who participated in clinical trials were approached. Patients were unselected for family history of cancer, age at onset, multifocal tumors, or personal history of multiple malignant tumors. All patients viewed a standard pretest education video and were offered pretest genetic counseling. If pathogenic or likely pathogenic variants were detected, patients discussed the results with a certified cancer genetic counselor (A.A.), who then coordinated family cascade testing, as appropriate. Clinical and family history data were obtained from medical records and self-administered questionnaires. Pathologic test results were reviewed by genitourinary pathologists (Y.-B.C.) at the institution. A total of 128 patients were previously described in a large series that covered multiple tumor types, including patients with localized disease who are not described here; clinical annotation, including RCC tumor subtypes, was also not reported. 18 The study was approved by the MSKCC Institutional Review Board. All patients provided written informed consent. Data were deidentified except to the investigators of the study.
Sequencing and Interpretation of Variants
Tumor and blood samples from patients were sequenced using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a next-generation sequencing assay that achieves hybridization capture with targetspecific probe from exons of at least 341 cancer-associated genes in the first iteration and 468 in the most recent, as described pre- 
Frequency of Mutations and Comparison With the Population
A total of 41 patients (16.1%) carried pathogenic or likely pathogenic germline variants in 17 different cancer-predisposition genes ( Figure 1) . No individuals had more than 1 germline mutation. Fourteen patients (5.5%) carried mutations in RCCassociated genes (7 in FH,3inBAP1, and 1 each in VHL, MET, SDHA, and SDHB). Twenty-seven patients (10.5%) carried mutations in genes not clearly associated with RCC, including 9 (3.5%) in CHEK2 (OMIM 604373); 2 of these were in the variant CHEK2 p.Ile157Thr, which is a low-penetrance breast cancer risk allele of uncertain actionability. 30 Of the 41 patients, 17 patients (41.5%) carried mutations of high penetrance, 9 (22.0%) of moderate penetrance, 12 (29.3%) of low penetrance or uncertain clinical actionability, and 3 (7.3%) in genes linked to autosomal recessive syndromes (eTable 5 in the Supplement). Of the 177 patients with ccRCC, 25 (14.1%) had a germline mutation and 3 (1.7%) in an RCC-associated gene ( Figure 2) . Of the 74 patients with nccRCC, 13 (17.5%) had a germline mutation, with 9 (12.2%) in an RCC-associated gene. Of the 3 patients with both ccRCC and nccRCC, all 3 had germline mutations, 2 in BAP1 and1inCHEK2.
For genes not traditionally associated with RCC, we compared mutation frequencies with those in the general population. The odds of mutations significantly exceeded the odds in the population only for CHEK2 (OR, 3.0; 95% CI, 1.3-5.8; P = .003) when all variants were considered (eTable 6 in the Supplement).
Factors Associated With Germline Mutations
We analyzed prevalence of mutations among patients thought to be at higher risk for inherited syndromes, including those with family history of RCC, early onset (≤46 years of age), and multifocal disease at diagnosis. Patients with nccRCC or multifocal RCC were significantly more likely to have an RCC-associated mutation (eTable 7 in the Supplement). Seven patients (9.5% of the nccRCC cohort) had germline FH mutations diagnostic of the hereditary syndrome HLRCC; all patients had tumors of unclassified histologic type or identified as FH deficient. All but one tumor, for which tissue was limited, were identified by genitourinary pathologists (Y.-B.C.) as suggestive of features of HLRCC. Median age at diagnosis for FH-positive patients was 49 years (range, 23-58 years); 4 presented with metastatic disease, and 3 later developed metastatic disease (range, 10 months to 10 years). None had multifocal RCC or family history of RCC. Of the other benign tumors associated with HLRCC, uterine fibroids were present in all women, but cutaneous leiomyomas were identified in only 1 patient after the HLRCC diagnosis was known.
Three patients had BAP1 mutations: a woman in her 60s with ccRCC, a man in his 40s with ccRCC and a chromophobe tumor, and a man in his 80s with ccRCC, multiple papillary tumors, and colon cancer (pedigrees in the eFigure in the Supplement). Staining for BAP1 protein showed lack of expression in the ccRCC tumors of all 3 patients and the chromophobe tumor (eFigure in the Supplement). The papillary tumors were not available for immunohistochemical analysis.
Application of Clinical Genetic Counseling Referral Criteria
Overall, 99 patients (39.0%) would have met ACMG criteria for clinical genetics referral. Of 14 patients with RCC-associated mutations, 5 (35.7%) would not have met referral criteria, including 3 patients with FH,1withVHL,and1withSDHA. Of 12 patients with high or moderate penetrance mutations not
have met referral criteria. At the time of analysis, at least 6 relatives of patients with mutations underwent germline testing through our clinic; several were also found to be carriers and referred for discussion of dedicated cancer screening.
Somatic Mutations in Patients With Germline Mutations
Tumor sequencing data were available for all but 1 patient. For 3 patients with both ccRCC and nccRCC, only the ccRCC was sequenced. In patients with germline mutations, we show the distribution of somatic variants and LOH in the tumor at the loci of interest ( Figure 3 ). Of 9 patients with germline CHEK2 mutations, 4 (44.4%) had LOH. Of 7 patients with germline FH mutations, 5 (71.4%) had LOH and 2 (28.6%) had a somatic second hit.
We investigated the clinical utility of tumor-only testing for guiding therapy using previously described methods. 31 No patients had a level 1 or level 2A standard of care somatic biomarker predictive of response in RCC. A total of 36 (14.2%) had a level 2B or 3 somatic mutation that was a predictive biomarker in other cancers but not routinely used in RCC (eTable 8intheSupplement).
Discussion
We report the prevalence of germline cancer-associated mutations in patients with advanced RCC unselected for suspicion of a hereditary syndrome. To date, approximately 5% of all RCC cases have been linked to high-penetrance cancer predisposition syndromes. 4 Most studies 14,15 on hereditary RCC, however, have been limited to selected, high-risk populations, and none to our knowledge have specifically studied patients with advanced disease. In this study, we found that among 254 patients with advanced RCC, 41 (16.1%) harbored pathogenic germline mutations, with 14 (5.5%) in RCC-associated genes and 27 (10.5%) in non-RCC-associated genes. The mutation rate was even higher among patients with uncommon RCC variants: more than 20% of patients with an nccRCC had germline mutations, of which half could help direct therapy according to previously published data from prospective clinical trials. 19, 20, 32, 33 Previous data 16, 17 suggest that the prevalence and spectrum of germline mutations differ between early-and latestage disease in several cancers. In an analysis of 1040 patients with diverse cancers, a recent study 18 found that the prevalence of germline, cancer-predisposing mutations was higher among patients with metastatic compared with localized disease (22.3% vs 8.3%; P < .001). In a separate study 34 of 1235 patients with RCC with all stages of disease who were referred for multigene germline testing, 6% had mutations, but the spectrum of mutations differed from that in our cohort.
The most frequent mutations were in FLCN (1.8% vs 0% in our cohort). Despite the enrichment in that series for suspected hereditary syndromes, FH mutations were less prevalent (1.3% vs 3% in our cohort) and only 2 BAP1 mutations were identified. FH and BAP1 mutations may be associated with more aggressive RCC, which could account for their overrepresentation in the current cohort of patients with advanced cancer. 35, 36 We found that 9% of all patients with advanced nccRCC had a germline FH mutation diagnostic of HLRCC, a higher percentage than previously reported. 37, 38 Hereditary leiomyomatosis and RCC is an autosomal dominant inherited syndrome associated with RCC and uterine and cutaneous leiomyomas. These patients were difficult to identify by clinical criteria. None had a family history of RCC, and typical cutaneous lesions were not identified by the treating oncologists. Although expert genitourinary pathologists identified histologic features suggestive of HLRCC, it is APC  CHEK2  MUTYH BAP1  FH   APC  ATM  CHEK2  MET  PALB2  RAD51C  RECQL4  RECQL4  EPCAM  MSH6  SDHA  VHL  BARD1  BRCA2 We also found that 2 of 3 individuals with BAP1 mutations had nccRCC tumors, which, to our knowledge, have never been reported in BAP1 carriers. 42 The available chromophobe tumor had loss of expression of BAP1 on immunohistochemical analysis, which is rare in chromophobe tumors. 43 The possible association of BAP1 mutations with nccRCC should be investigated in other cohorts. Novel biomarkers predictive of therapy response are needed in RCC. 31, 44 In this cohort, 10% of patients with nccRCC had a predictive germline biomarker, none of which would have been identified with somatic-only sequencing. In RCC, several germline mutations are prognostic indicators of response to therapies. In a phase 2 biomarker study 20 of a dual MET/VEGFR2 in patients with papillary RCC, the presence of a germline MET mutation was associated with response. Another phase 2 study 33 of bevacizumab plus erlotinib for patients with sporadic or hereditary papillary RCC showed significant activity with the combination, particularly in those with HLRCC. On the basis of this study, 33 the 2018 National Comprehensive Cancer Network guidelines added bevacizumab plus everolimus or erlotinib as options specifically for patients with germline FH mutations diagnostic of HLRCC.
45
Because of the high positive germline mutation rate among patients with nccRCC, the difficulty using clinical criteria to identify them, and the potential for therapeutic actionability, patients with advanced nccRCC should be referred for genetic counseling and appropriate testing. Compared with the general population, patients with RCC had a significantly increased frequency of germline CHEK2 mutations. Germline CHEK2 mutations are associated with increased susceptibility to several cancers. Few studies 46,47 have found an increased risk of RCC among carriers of the 1100deC truncating mutation and Polish founder mutations, with ORs ranging from 2.1 to 3.6. We found an OR of 3.0 of RCC when all variants of CHEK2 were considered. A potential role of CHEK2 in the pathogenicity of RCC is also supported by the LOH in the tumor in 4 of 9 germline CHEK2 mutants. Although there are currently no RCC-specific screening recommendations for individuals with CHEK2 mutations, there may be incremental screening for other cancers, justifying including this gene on RCC panel tests.
28
For patients with advanced RCC, current clinical guidelines for referral to genetic counseling miss patients who could benefit from genetic counseling. The ACMG has developed practice guidelines that consider age at diagnosis, tumor multifocality, family history, and histologic findings. 27 We found that despite almost 40% of patients in this cohort meeting the broad guideline criteria, 36% of patients with highpenetrance RCC-associated mutations would have been missed. With potentially increasing numbers of mutations identified in patients and relatives, optimal cancer screening schedules need to be studied. For example, there are no consensus screening guidelines for several of the more rare RCC genetic syndromes, including BAP1-associated cancer syndrome, although some groups have suggested screening schedules.
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Limitations
There are limitations to this study. Many patients in this cohort also participated in clinical trials. Therefore, patients who contributed to this study most likely were younger and had fewer comorbid conditions than the general cancer population. For example, the median age at diagnosis in this study was 56 years compared with 64 years in the United States. 1 Nevertheless, this limitation may underestimate the number with germline mutations because most trials exclude patients with a history of other malignant tumors. We acknowledge that some Ashkenazi Jewish founder mutations, such as APC (OMIM 611731) p.Ile1307Lys and CHEK2 p.Ser428Phe, may be overrepresented in our cohort. Although the association of APC and RCC risk is unclear, for CHEK2, we also performed a burden test excluding the p.Ser428Phe variant, and the association with RCC was still present (eTable 6 in Supplement). Finally, although we analyzed 254 patients, the sample size was still limited, and further studies should be conducted.
Conclusions
Our results suggest that germline mutations in cancerassociated genes in patients with advanced RCC may be prevalent, and many of these mutations can be used to guide therapy. Phenotype-directed or tumor-only testing would have failed to identify most patients with actionable mutations. A broader approach to tumor-normal sequencing of all patients with advanced RCC, especially those with nccRCC, might help identify individual patients for whom targeted therapies are indicated, as well as family members who may benefit from preventive interventions tailored to their increased cancer risk. 
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Broadening the View of Germline Mutations in Kidney Cancer
Patrick G. Pilié, MD; Kathleen A. Cooney, MD, MACP Next-generation sequencing has revolutionized precision oncology, with paired somatic and germline DNA variant analysis becoming more powerful and more widely accessible for clinical applications. The field of clinical cancer genetics previously relied primarily on a patient's personal and family medical history to delineate specific hereditary cancer syndromes that are associated with deleterious variants in specific genes. Tumor sequencing technology is currently used frequently in oncology with the goal of identifying deleterious gene variants that are actionable or druggable, resulting in the rapid proliferation of targeted anticancer therapies. Through this approach, a significant portion of patients have been incidentally found to have pathogenic or likely pathogenic germline mutations, and a previous study 1 found that patients with advanced cancers across tumor types are enriched for hereditary pathogenic variants in cancer-related genes. Of importance, many of these patients do not meet current clinical criteria for germline testing. Thus, mutations in genes that are potentially associated with a patient's cancer treatment and care, as well as cancer risk and prevention for the patient's family members, are going undiscovered. Hereditary renal cell carcinoma (RCC) syndromes are thought to account for approximately 5% of kidney cancers and arise from pathogenic variants in a diverse array of genes. The histologic features of RCC, family history of RCC, multifocal disease, age at onset of 46 years or younger, and/or the presence of other characteristic tumor types contribute to the decision to refer a patient to a clinical cancer geneticist for germline testing using targeted panels of RCC-related genes. 2, 3 It is well known that RCC histologic subtypes have distinct molecular profiles and driver mutations, and thus the histologic subtype of kidney cancer can suggest the presence of certain germline mutations. 3 However, the prevalence of pathogenic germline variants in patients with locoregional and/or metastatic RCC unselected for family history or other hereditary features has not been well evaluated. In addition, the presence of pathogenic germline variants in a broader set of cancerrelated genes outside canonical RCC-related genes has not been comprehensively described in this population. Endothelial cell within the "alveolar" fibrovasculatures show retained BAP1 nuclear expression (short arrows). Stromal and lymphocytic cells also show retain nuclear BAP1 expression.
